{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:15:44Z","timestamp":1791260144966,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,15]],"date-time":"2018-04-15T00:00:00Z","timestamp":1523750400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13054-018-2019-8","type":"journal-article","created":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T06:11:39Z","timestamp":1523599899000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Population pharmacokinetics\/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients"],"prefix":"10.1186","volume":"22","author":[{"given":"Emilio","family":"Maseda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Grau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Luque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Pilar","family":"Castillo-Mafla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Su\u00e1rez-de-la-Rica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Montero-Feijoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Salgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Jose","family":"Gimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Garc\u00eda-Bernedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Gilsanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,15]]},"reference":[{"key":"2019_CR1","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1017\/S0029665112000158","volume":"71","author":"JJ Milner","year":"2012","unstructured":"Milner JJ, Beck MA. The impact of obesity on the immune response to infection. Proc Nutr Soc. 2012;71:298\u2013306.","journal-title":"Proc Nutr Soc"},{"key":"2019_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1146\/annurev-pharmtox-010814-124354","volume":"55","author":"CA Knibbe","year":"2015","unstructured":"Knibbe CA, Brill MJ, van Rongen A, Diepstraten J, van der Graaf PH, Danhof M. Drug disposition in obesity: toward evidence-based dosing. Annu Rev Pharmacol Toxicol. 2015;55:149\u201367.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2019_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/clpt.2011.104","volume":"90","author":"R Jain","year":"2011","unstructured":"Jain R, Chung SM, Jain L, Khurana M, Lau SW, Lee JE, et al. Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol Ther. 2011;90:77\u201389.","journal-title":"Clin Pharmacol Ther"},{"key":"2019_CR4","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/CCM.0b013e3181961bff","volume":"37","author":"JA Roberts","year":"2009","unstructured":"Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009;37:840\u201351.","journal-title":"Crit Care Med"},{"key":"2019_CR5","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ijantimicag.2016.01.009","volume":"47","author":"AS Alobaid","year":"2016","unstructured":"Alobaid AS, Hites M, Lipman J, Taccone FS, Roberts JA. Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: a structured review. Int J Antimicrob Agents. 2016;47:259\u201368.","journal-title":"Int J Antimicrob Agents"},{"key":"2019_CR6","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1086\/501020","volume":"42","author":"PH Chandrasekar","year":"2006","unstructured":"Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin Infect Dis. 2006;42:1171\u20138.","journal-title":"Clin Infect Dis"},{"key":"2019_CR7","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/cid\/civ1194","volume":"62","author":"PG Pappas","year":"2016","unstructured":"Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Executive summary: clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62:409\u201317.","journal-title":"Clin Infect Dis"},{"key":"2019_CR8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13054-016-1229-1","volume":"20","author":"JA Paiva","year":"2016","unstructured":"Paiva JA, Pereira JM, Tabah A, Mikstacki A, de Carvalho FB, Koulenti D, et al. Characteristics and risk factors for 28-day mortality of hospital acquired fungemias in ICUs: data from the EUROBACT study. Crit Care. 2016;20:53.","journal-title":"Crit Care"},{"key":"2019_CR9","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1128\/AAC.01430-10","volume":"55","author":"D Andes","year":"2011","unstructured":"Andes D, Ambrose PG, Hammel JP, Van Wart SA, Iyer V, Reynolds DK, et al. Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia. Antimicrob Agents Chemother. 2011;55:2113\u201321.","journal-title":"Antimicrob Agents Chemother"},{"key":"2019_CR10","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1128\/CMR.00047-06","volume":"20","author":"J Turnidge","year":"2007","unstructured":"Turnidge J, Paterson DL. Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev. 2007;20:391\u2013408.","journal-title":"Clin Microbiol Rev"},{"key":"2019_CR11","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1093\/jac\/dku013","volume":"69","author":"E Maseda","year":"2014","unstructured":"Maseda E, Grau S, Villagran MJ, Hernandez-Gancedo C, Lopez-Tofi\u00f1o A, Roberts JA, et al. Micafungin pharmacokinetic\/pharmacodynamic adequacy for the treatment of invasive candidiasis in critically ill patients on continuous venovenous haemofiltration. J Antimicrob Chemother. 2014;69:1624\u201332.","journal-title":"J Antimicrob Chemother"},{"key":"2019_CR12","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1001\/jama.1993.03510240069035","volume":"270","author":"JR Le Gall","year":"1993","unstructured":"Le Gall JR, Lemeshow S, Saulnier F. A new simplified acute physiologic score (SAPS-II) based on a European\/North-American multicenter study. JAMA. 1993;270:2957\u201363.","journal-title":"JAMA"},{"key":"2019_CR13","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/BF01709751","volume":"22","author":"JL Vincent","year":"1996","unstructured":"Vincent JL, Moreno R, Takala J, Willatts S, De Mendon\u00e7a A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. Intensive Care Med. 1996;22:707\u201310.","journal-title":"Intensive Care Med"},{"key":"2019_CR14","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1097\/01.CCM.0000202208.37364.7D","volume":"34","author":"C Le\u00f3n","year":"2006","unstructured":"Le\u00f3n C, Ruiz-Santana S, Saavedra P, Almirante B, Nolla-Salas J, Alvarez-Lerma F, et al. A bedside scoring system (\u201cCandida score\u201d) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med. 2006;34:730\u20137.","journal-title":"Crit Care Med"},{"key":"2019_CR15","doi-asserted-by":"publisher","first-page":"e01276","DOI":"10.1128\/AAC.01276-16","volume":"61","author":"AS Alobaid","year":"2017","unstructured":"Alobaid AS, Wallis SC, Jarrett P, Starr T, Stuart J, Lassig-Smith M, et al. Population pharmacokinetics of piperacillin in nonobese, obese, and morbidly obese critically ill patients. Antimicrob Agents Chemother. 2017;61:e01276\u2013316.","journal-title":"Antimicrob Agents Chemother"},{"key":"2019_CR16","volume-title":"Guidance for industry: bioanalytical method validation","author":"Food and Drug Administration","year":"2001","unstructured":"Food and Drug Administration. Guidance for industry: bioanalytical method validation. Rockville: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM); 2001."},{"key":"2019_CR17","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10928-013-9302-8","volume":"40","author":"T Tatarinova","year":"2013","unstructured":"Tatarinova T, Neely M, Bartroff J, van Guilder M, Yamada W, Bayard D, et al. Two general methods for population pharmacokinetic modelling: non-parametric adaptive grid and non-parametric Bayesian. J Pharmacokinet Pharmacodyn. 2013;40:189\u201399.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2019_CR18","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/FTD.0b013e31825c4ba6","volume":"34","author":"MN Neely","year":"2012","unstructured":"Neely MN, van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit. 2012;34:467\u201376.","journal-title":"Ther Drug Monit"},{"key":"2019_CR19","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s10928-005-0016-4","volume":"33","author":"F Mentr\u00e9","year":"2006","unstructured":"Mentr\u00e9 F, Escolano S. Prediction discrepancies for the evaluation of nonlinear mixed-effects models. J Pharmacokinet Pharmacodyn. 2006;33:345\u201367.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2019_CR20","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1128\/JCM.00308-13","volume":"51","author":"MA Pfaller","year":"2013","unstructured":"Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol. 2013;51:2571\u201381.","journal-title":"J Clin Microbiol"},{"issue":"3","key":"2019_CR21","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s40262-017-0578-5","volume":"57","author":"Roeland E. Wasmann","year":"2017","unstructured":"Wasmann RE, Muilwijk EW, Burger DM, Verweij PE, Knibbe CA, Br\u00fcggemann RJ. Clinical pharmacokinetics and pharmacodynamics of micafungin. Clin Pharmacokinet. 2017; \n                    https:\/\/doi.org\/10.1007\/s40262-017-0578-5\n                    \n                  . [Epub ahead of print].","journal-title":"Clinical Pharmacokinetics"},{"key":"2019_CR22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1093\/jac\/dkw352","volume":"72","author":"V Jullien","year":"2017","unstructured":"Jullien V, Azoulay E, Schwebel C, Le Saux T, Charles PE, Cornet M, et al. Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation. J Antimicrob Chemother. 2017;72:181\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"2019_CR23","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1128\/AAC.00623-15","volume":"59","author":"VJ Lempers","year":"2015","unstructured":"Lempers VJ, Schouten JA, Hunfeld NG, Colbers A, van Leeuwen HJ, Burger DM, et al. Altered micafungin pharmacokinetics in intensive care unit patients. Antimicrob Agents Chemother. 2015;59:4403\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"2019_CR24","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s40262-017-0509-5","volume":"56","author":"Lisa C. Martial","year":"2017","unstructured":"Martial LC, Ter Heine R, Schouten JA, Hunfeld NG, van Leeuwen HJ, Verweij PE, et al. Population pharmacokinetic model and pharmacokinetic target attainment of micafungin in intensive care unit patients. Clin Pharmacokinet. 2017; \n                    https:\/\/doi.org\/10.1007\/s40262-017-0509-5\n                    \n                  . [Epub ahead of print].","journal-title":"Clinical Pharmacokinetics"},{"key":"2019_CR25","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1007\/s00204-016-1916-3","volume":"91","author":"CC Chang","year":"2017","unstructured":"Chang CC, Slavin MA, Chen SC. New developments and directions in the clinical application of the echinocandins. Arch Toxicol. 2017;91:1613\u201321.","journal-title":"Arch Toxicol"},{"key":"2019_CR26","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.diagmicrobio.2007.09.018","volume":"60","author":"T Gumbo","year":"2008","unstructured":"Gumbo T, Hiemenz J, Ma L, Keirns JJ, Buell DN, Drusano GL. Population pharmacokinetics of micafungin in adult patients. Diagn Microbiol Infect Dis. 2008;60:329\u201331.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2019_CR27","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.1128\/AAC.05193-11","volume":"55","author":"RG Hall","year":"2011","unstructured":"Hall RG, Swancutt MA, Gumbo T. Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people. Antimicrob Agents Chemother. 2011;55:5107\u201312.","journal-title":"Antimicrob Agents Chemother"},{"key":"2019_CR28","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/cpt.38","volume":"97","author":"JP Pasipanodya","year":"2015","unstructured":"Pasipanodya JP, Hall RG 2nd, Gumbo T. In silico-derived bedside formula for individualized micafungin dosing for obese patients in the age of deterministic chaos. Clin Pharmacol Ther. 2015;97:292\u20137.","journal-title":"Clin Pharmacol Ther"},{"key":"2019_CR29","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1128\/AAC.01584-09","volume":"54","author":"D Andes","year":"2010","unstructured":"Andes D, Diekema DJ, Pfaller MA, Bohrmuller J, Marchillo K, Lepak A. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob Agents Chemother. 2010;54:2497\u2013506.","journal-title":"Antimicrob Agents Chemother"},{"key":"2019_CR30","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(07)60605-9","volume":"369","author":"ER Kuse","year":"2007","unstructured":"Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet. 2007;369:1519\u201327.","journal-title":"Lancet"},{"key":"2019_CR31","doi-asserted-by":"publisher","first-page":"6550","DOI":"10.1128\/AAC.01088-16","volume":"60","author":"AS Alobaid","year":"2016","unstructured":"Alobaid AS, Wallis SC, Jarrett P, Starr T, Stuart J, Lassig-Smith M, et al. Effect of obesity on the population pharmacokinetics of fluconazole in critically ill patients. Antimicrob Agents Chemother. 2016;60:6550\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"2019_CR32","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s40262-016-0401-8","volume":"55","author":"VJ Lempers","year":"2016","unstructured":"Lempers VJ, van Rongen A, van Dongen EP, van Ramshorst B, Burger DM, Aarnoutse RE, et al. Does weight impact anidulafungin pharmacokinetics? Clin Pharmacokinet. 2016;55:1289\u201394.","journal-title":"Clin Pharmacokinet"},{"key":"2019_CR33","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.ijantimicag.2016.02.004","volume":"47","author":"Q Yang","year":"2016","unstructured":"Yang Q, Wang T, Xie J, Wang Y, Zheng X, Chen L, et al. Pharmacokinetic\/pharmacodynamic adequacy of echinocandins against Candida spp. in intensive care unit patients and general patient populations. Int J Antimicrob Agents. 2016;47:397\u2013402.","journal-title":"Int J Antimicrob Agents"},{"key":"2019_CR34","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1093\/jac\/dkr323","volume":"66","author":"A Zomp","year":"2011","unstructured":"Zomp A, Bookstaver PB, Ahmed Y, Turner JE, King C. Micafungin therapy in a critically ill, morbidly obese patient. J Antimicrob Chemother. 2011;66:2678\u201380.","journal-title":"J Antimicrob Chemother"},{"key":"2019_CR35","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1001\/jama.2016.6458","volume":"315","author":"KM Flegal","year":"2016","unstructured":"Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in obesity among adults in the United States, 2005 to 2014. JAMA. 2016;315:2284\u201391.","journal-title":"JAMA"},{"key":"2019_CR36","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/sj.bmt.1705398","volume":"38","author":"B Sirohi","year":"2006","unstructured":"Sirohi B, Powles RL, Chopra R, Russell N, Byrne JL, Prentice HG, et al. A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant. 2006;38:47\u201351.","journal-title":"Bone Marrow Transplant"},{"key":"2019_CR37","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1086\/520980","volume":"45","author":"PG Pappas","year":"2007","unstructured":"Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007;45:883\u201393.","journal-title":"Clin Infect Dis"},{"key":"2019_CR38","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/ajh.21858","volume":"85","author":"N Goto","year":"2010","unstructured":"Goto N, Hara T, Tsurumi H, Ogawa K, Kitagawa J, Kanemura N, et al. Efficacy and safety of micafungin for treating febrile neutropenia in hematological malignancies. Am J Hematol. 2010;85:872\u20136.","journal-title":"Am J Hematol"},{"key":"2019_CR39","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/jac\/dkm125","volume":"60","author":"TH Nguyen","year":"2007","unstructured":"Nguyen TH, Hoppe-Tichy T, Geiss HK, Rastall AC, Swoboda S, Schmidt J, et al. Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit. J Antimicrob Chemother. 2007;60:100\u20136.","journal-title":"J Antimicrob Chemother"},{"key":"2019_CR40","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1128\/AAC.01490-12","volume":"57","author":"RG Hall","year":"2013","unstructured":"Hall RG, Swancutt MA, Meek C, Leff R, Gumbo T. Weight drives caspofungin pharmacokinetic variability in overweight and obese people: fractal power signatures beyond two-thirds or three-fourths. Antimicrob Agents Chemother. 2013;57:2259\u201364.","journal-title":"Antimicrob Agents Chemother"},{"key":"2019_CR41","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s13054-017-1774-2","volume":"21","author":"R Ferriols-Lisart","year":"2017","unstructured":"Ferriols-Lisart R, Aguilar G, P\u00e9rez-Pitarch A, Puig J, Ezquer-Gar\u00edn C, Al\u00f3s M. Plasma concentrations of caspofungin in a critically ill patient with morbid obesity. Crit Care. 2017;21:200.","journal-title":"Crit Care"},{"key":"2019_CR42","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1128\/AAC.02139-12","volume":"57","author":"P Liu","year":"2013","unstructured":"Liu P, Ruhnke M, Meersseman W, Paiva JA, Kantecki M, Damle B. Pharmacokinetics of anidulafungin in critically ill patients with candidemia\/ invasive candidiasis. Antimicrob Agents Chemother. 2013;57:1672\u20136.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-018-2019-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13054-018-2019-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-018-2019-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,14]],"date-time":"2019-04-14T19:04:09Z","timestamp":1555268649000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-018-2019-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,15]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2019"],"URL":"https:\/\/doi.org\/10.1186\/s13054-018-2019-8","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,15]]},"assertion":[{"value":"25 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Ethics Committee of Hospital La Paz (Madrid, Spain) and Hospital del Mar (Barcelona, Spain). Written informed consent was obtained from patients (or relatives if the patient was unable to provide due to their critical situation) before blood sampling.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"EM has received consultancy fees and payment for lectures from Astellas Pharma S.A. (Madrid, Spain), Pfizer, Novartis, Angellini, and Merck Sharp and Dohme. SG has received grants for research from Astellas Pharma S.A. (Madrid, Spain), Pfizer, Roche Pharma, and Angelini Pharma, and funds for speaking at symposia organized by Pfizer, Astellas Pharma S.A., and Merck Sharp and Dohme. SL has received travel grants from Astellas Pharma for medical conference attendance. CAG-B has received travel grants from Astellas Pharma for Sepsis Valladolid 2014 Congress attendance. The remaining authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"94"}}